Several other equities research analysts have also recently weighed in on KURA. Oppenheimer Holdings Inc. restated an outperform rating and set a $16.00 target price on shares of Kura Oncology in a report on Tuesday, June 21st. Zacks Investment Research upgraded Kura Oncology from a hold rating to a buy rating and set a $3.75 target price for the company in a report on Wednesday, July 13th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Kura Oncology has an average rating of Buy and an average target price of $14.15.
Shares of Kura Oncology (NASDAQ:KURA) opened at 5.35 on Thursday. Kura Oncology has a 12-month low of $2.50 and a 12-month high of $25.00. The stock’s 50 day moving average price is $6.16 and its 200 day moving average price is $4.23. The company’s market cap is $100.28 million.
Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.02. On average, analysts forecast that Kura Oncology will post ($1.58) EPS for the current year.
An institutional investor recently bought a new position in Kura Oncology stock. Alethea Capital Management LLC acquired a new stake in Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned approximately 0.34% of Kura Oncology at the end of the most recent quarter. 43.63% of the stock is owned by institutional investors and hedge funds.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.